Revumenib safe, effective in AML related to NPM1 mutations
Oral therapy revumenib showed positive results in patients with relapsed or refractory acute myeloid leukemia (AML) driven by NPM1 mutations, with nearly half of participants…
Latest news & perspectives
Adding VCN-01 extends survival in metastatic pancreatic cancer trial
Theriva Biologics’ experimental treatment VCN-01 safely increased survival when used in addition to chemotherapy for people with newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC),…
Viralgen, Trogenix collaborate on glioblastoma treatment
Contract development and manufacturing organization Viralgen said it has scaled up production of Trogenix’s glioblastoma treatment TGX-007, as the companies move the gene therapy…
